"Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the human BREAST.
| Descriptor ID |
D001943
|
| MeSH Number(s) |
C04.588.180 C17.800.090.500
|
| Concept/Terms |
Breast Neoplasms- Breast Neoplasms
- Breast Neoplasm
- Neoplasm, Breast
- Breast Tumors
- Breast Tumor
- Tumor, Breast
- Tumors, Breast
- Neoplasms, Breast
Breast Carcinoma- Breast Carcinoma
- Breast Carcinomas
- Carcinoma, Breast
- Carcinomas, Breast
Mammary Neoplasms, Human- Mammary Neoplasms, Human
- Human Mammary Neoplasm
- Human Mammary Neoplasms
- Neoplasm, Human Mammary
- Neoplasms, Human Mammary
- Mammary Neoplasm, Human
Breast Cancer- Breast Cancer
- Cancer, Breast
- Mammary Cancer
- Cancer, Mammary
- Cancers, Mammary
- Mammary Cancers
- Malignant Neoplasm of Breast
- Breast Malignant Neoplasm
- Breast Malignant Neoplasms
- Malignant Tumor of Breast
- Breast Malignant Tumor
- Breast Malignant Tumors
- Cancer of Breast
- Cancer of the Breast
|
Below are MeSH descriptors whose meaning is more general than "Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Breast Neoplasms".
This graph shows the total number of publications written about "Breast Neoplasms" by people in this website by year, and whether "Breast Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 13 | 2 | 15 |
| 1997 | 21 | 4 | 25 |
| 1998 | 24 | 4 | 28 |
| 1999 | 16 | 1 | 17 |
| 2000 | 16 | 7 | 23 |
| 2001 | 16 | 5 | 21 |
| 2002 | 11 | 7 | 18 |
| 2003 | 34 | 9 | 43 |
| 2004 | 25 | 7 | 32 |
| 2005 | 54 | 5 | 59 |
| 2006 | 45 | 7 | 52 |
| 2007 | 36 | 3 | 39 |
| 2008 | 39 | 6 | 45 |
| 2009 | 50 | 11 | 61 |
| 2010 | 59 | 11 | 70 |
| 2011 | 54 | 12 | 66 |
| 2012 | 46 | 6 | 52 |
| 2013 | 63 | 15 | 78 |
| 2014 | 58 | 14 | 72 |
| 2015 | 93 | 9 | 102 |
| 2016 | 60 | 11 | 71 |
| 2017 | 66 | 8 | 74 |
| 2018 | 76 | 4 | 80 |
| 2019 | 60 | 8 | 68 |
| 2020 | 63 | 13 | 76 |
| 2021 | 70 | 6 | 76 |
| 2022 | 59 | 1 | 60 |
| 2023 | 60 | 3 | 63 |
| 2024 | 52 | 5 | 57 |
| 2025 | 57 | 4 | 61 |
| 2026 | 23 | 0 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Breast Neoplasms" by people in Profiles.
-
The longitudinal effects of faith and meaning on quality of life in US women with breast cancer undergoing chemotherapy. Palliat Support Care. 2026 Jun 10; 24:e164.
-
Risk of malignancy after diagnosis of radial sclerosing lesion without atypia. Breast Cancer Res Treat. 2026 Jun 08; 217(2).
-
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis. Cancer Lett. 2026 Sep 01; 655:218636.
-
Individual and Co-Occurring Social Needs, and Breast and Cervical Cancer Screening Among Patients in Texas Federally Qualified Health Centers. J Prim Care Community Health. 2026 Jan-Dec; 17:21501319261448952.
-
Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative. Adv Ther. 2026 May; 43(5):1855-1868.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
Beyond TG-43: A PRISMA-based systematic review on model-based dose-calculation algorithms in brachytherapy. J Appl Clin Med Phys. 2026 May; 27(5):e70627.
-
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res. 2026 Apr 15; 32(8):1454-1461.
-
Comparing Neighborhood Indices of Socioeconomic Status, Segregation, and Healthcare Access for Predicting Late-Stage Breast Cancer. J Urban Health. 2026 Apr; 103(2):395-405.
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.